Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Pramipexole Tablets in Healthy Participants
NCT07727785Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pramipexole in Parkinson's disease (PD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve and Maximum measured concentration. Started Aug 2026; status: completed.
02
Drugs
pramipexole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07727785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07727785.